

Project	What's the product?	What's the problem?	Comments / questions to the team
InhibitecAnticuerpos	new treatment for psoriasis by a new target BAMBI	Psoriasis Resistance of the current therapies by many patients Murine molecule Regulatory requirements	What do you know about the specificity of this drug? What is the difference between the current anti-IL17 antibodies? What is the improvement of your treatment?
InhibitecAnticuerpos	a novel drug (antibody) to treat ADs.	AD is a major healthcare problem	-would like to see the benefits of the drug over existing competitions
InhibitecAnticuerpos	Drug to treat inflammatory auto immune disease	Current solutions have many side effects	Want to empathize why your solution is better
InhibitecAnticuerpos	30 % of patients do not respond to the treatment	anti-BAMBI for treatment of AD	
InhibitecAnticuerpos	Antibody drug for treating psoriasis to a new target	Current drugs don't work for everyone	Is there evidence that this target will work on that subset of patients that don't respond to the current treatments? What's known about the mechanism of the other drugs and why they don't work?
InhibitecAnticuerpos	antibody Tx for psoriasis	Many with psoriasis are not responsive to current therapies	You might have said: do you have evidence that this drug will be effective in cases where current therapy is not?
InhibitecAnticuerpos	novel BAMBI antibody		Need more background on how BAMBI differs from existing mechanisms. Would like to see deeper drill-down on % pts refractory and % develop resistance over what time period. Will you be able to put the humanized antibody into the murine models? What is the cross-reactivity. What other diseases may this be applicable to? If a patient is resistance to IL-17 antibodies will they also be resistant to BAMBI?

InhibitecAnticuerpos	New treatment for autoimmune diseases	Not very clear - assume it is that new treatment drugs are needed for Psoriasis	Not a clear description of how big the problem is? What is market size? What is path to commercialization? What is the clear value proposition?
InhibitecAnticuerpos	An antibody (murine) that recognises a target for psoriasis. The target is called BAMBI, and the antibody has the capacity to block psoriasis-derived inflammation and protect skin cells from the immune system.	Psoriasis, a disease with a high socioeconomic cost. The patients normally have high risk of depression and anxiety.	How are you going to move to the humanised antibody tests and specially throughout the preclinical trials? Will you use also animal models to test the humanised Ab?
InhibitecAnticuerpos	A novel antibody targeting BAMBI to treat psoriasis	There are patients unresponsive to current treatments Some resistance to treatments	What is the IPR status of the project? Have you compared in your murine model with other competitors? What is your advantage compared to other antibodies in the market or in the pipeline for psoriasis?
InhibitecAnticuerpos	new therapy for psoriasis	Significant amount of patients are irresponsive to current therapies or develop resistance over time	Competitors? Cost-effective therapy? Maybe considering change the name of company to a more international name. IP status?
InhibitecAnticuerpos	New treatment for psoriasis; Target is BAMBI (BMP and Activin Membrane Bound Inhibitor)	Need to find new tx targets and drugs; psoriasis affects 2-3 percent of the population, varies by country, up to 12% in Norway	Do you have funding to do the humanization of the antibody? Has anyone ever explored this target previously. Do you have IP around the target, or around the antibody? Why do you have regulatory issues identified in the first step vs preclinical development plan? What milestones have you achieved to date? Would like to see competitive landscape with all of the new psoriasis treatments emerging.

InhibitecAnticuerpos	anti-BAMBI mAb for psoriasis	lack of treatments for psoriasis	Consider learning about the competition --> what other mechanisms are currently in development by industry and how do you think you compare?
InhibitecAnticuerpos	Antibody treatment for psoriasis	A set of patients with severe psoriasis are drug resistant to current treatments	- Narrow down the number of severe patients that are drug resistant to current treatment for psoriasis to understand better how many from all the \$125M people you mentioned. - Use this number to explain the potential impact, including market size, of what you are trying to achieve.
InhibitecAnticuerpos	New immunotherapy for psoriasis	psoriasis, many patient remain unresponsive to current drugs or they develop drug resistance	Not clear why the team is here. The presenter implies that they have everything in place to produce a successful immunotherapy drug. What do they want to learn in IDEA2?
InhibitecAnticuerpos	Cure for Psoriasis	Psoriasis is a disease with an important quality-of-life impact	What is the best alternative available today to solve this? I'd like to know how this compares to the current competition.
InhibitecAnticuerpos	An anti-BAMBI antibody for psoriasis	Current therapies for psoriasis and psoriatic arthritis can lead to resistance or non-response; there is a need for new therapies	Do you have any backup molecules? What is your IP status around the murine and human B101? How does your molecule compare in terms of other important parameters (PK, safety, dosing regimen) to existing psoriasis drugs like Cosentyx?
InhibitecAnticuerpos	molecule to treat psoriatic arthritis	need for more effective drugs for psoriatic arthritis	- how does ur molecule compare to existing immune modulators like MTX for psoriatic arthritis - what are the potential side effects
InhibitecAnticuerpos	BAMBI antibody to treat psoriasis	A lack of effective psoriasis treatments.	What do you want to gain from the Idea2 experience?
InhibitecAnticuerpos	Medicine for psoriasis treatment.	Psoriasis	
InhibitecAnticuerpos	Have developed an antibody that is therapeutic for psoriasis	Many patients are unresponsive to current existing drugs	What is the mouse model that your antibody is being tested? How similar is it to human psoriasis? Is your

			target market restricted to patients that are non-responsive to other drugs?
InhibitecAnticuerpos	Therapeutic for Psoriasis	Psoriasis	<ul style="list-style-type: none"> - How are you getting through trials - How are you demonstrating a higher degree of efficacy over standard of care/existing therapies - What are the side effects - What is your commercialization strategy
InhibitecAnticuerpos	Ab therapy for psoriasis	Psoriasis	I'm interested more the the biochemical and cell biological mechanism and how/why it works.
InhibitecAnticuerpos	antibody to treat psoriasis	current treatments not effective	clear and concise
InhibitecAnticuerpos	Antibodies targeting psoriasis	Unresponsive Psoriasis	<p>What is the population size that suffers from psoriasis? How big is the "significant fraction" of unresponsive patients? How frequently do patients develop drug resistance? It is important to quantify them.</p>
InhibitecAnticuerpos	Medicine for psoriasis treatment.	Psoriasis disease.	
InhibitecAnticuerpos	Identifying inhibitors for Psoriasis with fewer side effects	Psoriasis medication is not as effective	
InhibitecAnticuerpos	new drug to treat psoriasis	psoriasis is common: 125M have it and a "significant number" aren't responsive (? how many?)	- this is a very early stage project; should identify real market need size, target potential pharma companies that are in this space, begin to establish relationships, etc.
InhibitecAnticuerpos	Antibody for autoimmune disease	Treatment of psoriasis. Very common diseases but in severe psoriasis there are resistance for the therapies	Regulatory pathway.? Business model?

InhibitecAnticuerpos	Anti-BAMBI mono clonal antibody	Current therapy to address autoimmune disease is not very specific or targeted	
InhibitecAnticuerpos	BAMBI	Psoriasis and its related effects: unresponsive to existing therapies	-
InhibitecAnticuerpos	antibody to inhibit new target	psoriatic arthritis - can result in depression etc	